Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform

HAIFA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading biotechnology company, today announced that it has received approval for an...
September 22, 2021 08:15 ET | Source: Pluristem Therapeutics, Inc.

Pluristem CEO Issues Shareholder Update

HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief...
July 19, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof....
July 08, 2021 07:10 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and IsraelTopline results are expected during the fourth quarter of 2021 HAIFA, Israel,...
May 25, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank

HAIFA, Israel, May 25, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced the receipt of a “Disbursement...
April 29, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans

New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatmentsThe company will conduct an analyst and investor call on...
February 02, 2021 08:30 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering

HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
January 27, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Announces Uplisting to the Nasdaq Global Market®

HAIFA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
January 06, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Announces Appointments of Two Directors to Board

HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
December 29, 2020 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to Mexico

HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...